This technology is a therapeutic method utilizing bromodomain-containing proteins to treat drug-resistant basal cell carcinomas (BCCs).
Basal cell carcinomas (BCCs) are a prevalent form of malignant skin cancer; genetic conditions such as basal cell nevus syndrome (BCNS) and Gorlin-Goltz syndrome promote the uncontrolled growth of BCCs. BCCs are commonly treated with FDA-approved Smoothened (SMO) inhibitors, including vismodegib or sonidegib. However, drug resistance is extremely common, limiting the effectiveness of treatment options for patients.
This technology is a therapeutic that combines the use of BRD7 and BRD9 inhibitors to treat basal cell carcinomas (BCCs) that were previously resistant to FDA-approved Smoothened (SMO) inhibitors. Bromodomain-containing proteins are identified as dysregulated in drug-resistant BCCs. By modulating protein levels, the potency of BCC to SMO inhibitors is restored, significantly increasing efficiency in BCC treatment options and combination therapies.
Patent Pending
IR CU17184
Licensing Contact: Sara Gusik